Archive for the ‘Virus Killer’ Category

Gerson: Polio: A killer on the run

ATLANTA

Following a walk through nearly empty hallways, there is no receptionist at Thomas Friedens outer office. Just a ring-for-service sign. The director of the Centers for Disease Control and Prevention (CDC) is trying to manage a partial shutdown at an institution where nearly everything is ultimately a matter of life or death. The longer it goes, he said, the more complex it is. What isnt an imminent threat to health on Day Four is on Day 10.

As of now, eight of 10 global disease detection centers the field offices where outbreaks are identified and countered are closed. No processing of blood samples for parasitic diseases is taking place. No testing of counterfeit malaria medicines.

Fortunately, the CDCs polio eradication effort has been largely exempted from the shutdown. It is part of one of the most ambitious medical enterprises in history attempting to eliminate a highly contagious virus from the wild. This has been achieved only twice before, with smallpox and rinderpest. The end of polio transmission is a few hundred yearly cases away. Even a brief pause would risk losing ground.

Poliovirus which destroys neuron cells controlling swallowing, breathing and the use of limbs was once a source of seasonal panic in the United States. Epidemics (usually arriving in summer) sometimes caused states to close their borders, with inspectors demanding certificates of health for children younger than 16. American infections peaked at nearly 58,000 in 1952. (Sen. Mitch McConnell and Rep. Steve Cohen were both infected as children.) As late as 2004, dozens of Americans still lived in iron lungs.

But the use of the Salk and Sabin vaccines has chased the virus across the planet. The last American infections were in 1979 (among Amish who resisted vaccination). This was also the year that Rotary International started a campaign to eliminate polio transmission in the Philippines, beginning a global eradication movement that now includes the World Health Organization, UNICEF, the Gates Foundation and the CDC. In 1999, type 2 poliovirus (of three types) was eliminated in the wild. India has been polio-free since 2011 an important proof of concept. (If polio can be eliminated in northern India with its dense population and poor sanitary conditions it can be defeated anywhere.)

More than 99 percent of poliovirus transmission has been stopped over the past few decades. But the final bit is the hardest.

In 2011, an independent review panel questioned whether the opportunity for polio eradication was being squandered. It lit a fire under the movement. Partners increased their commitments. Frieden moved his effort into the CDCs Emergency Operations Center a high-tech amphitheater in which the disease is minutely tracked in maps and charts.

There are two regions where wild polio transmission has never been eradicated: in the tribal areas along the Afghanistan-Pakistan border and in northern Nigeria. In Afghanistan, efforts by the ministry of health have been innovative and successful. There have been only six cases so far this year, all of which (when the CDC examined the genetic fingerprints of the viruses) originated in Pakistan. In Pakistan, infections are largely confined to North Waziristan, where the local Taliban commander has banned vaccination. In Nigeria, the government has recently improved the management of its program and infections are down. But the terrorist group Boko Haram which rejects everything Western, including vaccines and education is suspected of being responsible for the murders of nine polio workers this year. Polio is a killer that finds allies among killers.

Now a virus originating in Nigeria has caused an outbreak in Somalia, which has spread some cases to Kenya and Ethiopia. Health authorities in Mogadishu responded with surprising celerity, beginning immunizations four days after the first reported illness. But the problem persists in less-populated areas controlled by the jihadist group al-Shabab. Somalia, which has ended polio transmission twice before, must do it a third time.

Continue reading here:
Gerson: Polio: A killer on the run

GeoVax Receives Notice of Patent Allowance for DNA/MVA Vaccine for HIV/AIDS

ATLANTA, GA--(Marketwired - Oct 7, 2013) - GeoVax Labs, Inc. (OTCQB: GOVX), a biotechnology company developing preventive and therapeutic HIV vaccines, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for patent application U.S. 10/336,566 entitled, "Compositions and Methods for Generating an Immune Response." The patent, exclusively licensed from Emory University and the U.S. Government, broadly covers compositions, methods, and uses of the GeoVax's DNA/MVA vaccine in eliciting cellular and humoral immune responses to an HIV antigen.

The allowed claims pursuant to the patent cover advances in the DNA construct portion of GeoVax's vaccine. The DNA construct forms the priming vaccine in the GeoVax HIV vaccine regimen and is followed by boosting administrations made up of a modified vaccinia Ankara (MVA) construct. Preclinical studies in primates have shown that simian analogs of GeoVax's DNA/MVA vaccine provide up to 78% per exposure protection against SIV251, a highly virulent strain of simian immunodeficiency virus. Phase 1 testing in humans is ongoing in a trial sponsored by the HIV Vaccine Trials Network, with plans for Phase 2 initiation in 2014.

"This patent is key to the commercialization of our DNA/MVA HIV vaccine technology," said Robert T. McNally, PhD, President and CEO of GeoVax. "We are pleased that the USPTO has confirmed that the claims in our patent application are patentable over the prior art of record."

About GeoVax's TechnologyGeoVax's unique, two component vaccine, a recombinant DNA and a recombinant modified vaccinia Ankara (MVA), is designed to stimulate both anti-HIV T cell and anti-HIV antibody immune responses. GeoVax's DNA and MVA vaccines are used in a prime/boost protocol in which priming is done with the DNA and boosting with the MVA. Both the DNA and MVA express the three major proteins of the AIDS virus: Gag, Pol, and Env, and produce non-infectious virus-like-particles. GeoVax's vaccines are unique in expressing virus-like particles that display the trimeric membrane bound form of the HIV-1 envelope glycoprotein. In GeoVax's second generation vaccine, the DNA prime co-expresses GM-CSF with the virus-like particles, delivering a normal human protein that stimulates immune responses to the site of vaccination. All preventative Phase 1 human clinical trials conducted to date tested various combinations and doses of the DNA and MVA vaccines, their ability to raise anti-HIV humoral (antibody) and cellular (cytotoxic T cell) immune responses, as well as the vaccines' safety. For more information, please visit http://www.geovax.com.

About HIV/AIDS AIDS is an epidemic that can affect anyone, regardless of race, gender, age or sexual orientation. 33 million people are currently infected globally; it is estimated that there will be 2.5 million new infections this year. Since the beginning of the epidemic, more than a million people in the U.S. have contracted the virus. More than a quarter of new US infections are in youths aged 13 to 24; and of those, 60 percent do not know they are infected. Globally, HIV is the top killer among women of reproductive age. HIV is a worldwide disease with different subtypes (or clades) of the virus predominating in different regions of the world. Clade B is the predominant subtype in North America. Globally, most infections involve subtypes AG, B and C. GeoVax vaccines are currently designed to function against clade B.

Forward-Looking StatementsCertain statements in this document are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax can develop and manufacture its vaccines with the desired characteristics in a timely manner, GeoVax's vaccines will be safe for human use, GeoVax's vaccines will effectively prevent AIDS in humans, vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete vaccine development, there is development of competitive products that may be more effective or easier to use than GeoVax's products, GeoVax will be able to enter into favorable manufacturing and distribution.

See the article here:
GeoVax Receives Notice of Patent Allowance for DNA/MVA Vaccine for HIV/AIDS

Health officials worry county freeholders could bite into mosquito control program

At a time when the mosquito-borne West Nile virus is still a potential killer, health officials are worried that a reorganization plan by the Morris County Freeholders will cut mosquito control efforts.

The freeholders plan to eliminate the all-volunteer Morris County Mosquito Extermination Commission, and fold the paid mosquito control staff that the commission oversees into the countys Department of Planning and Public Works.

The proposed reorganization is expected to go into effect after the freeholders January reorganization.

The plan comes not long after a 92-year-old Morris County resident died Aug. 31 after contracting West Nile.

This past summers first detection of infected mosquitoes in Morris County was on Aug. 1 at Donatoni Community Park on West Main Street in Rockaway. A week later, the park and surrounding woods, path and access road were treated by the mosquito commission.

As of Sept. 27, mosquitoes carrying West Nile have been found in 44 pools in Morris County, according to the N.J. Department of Health.

Morris County Freeholder David Scapicchio, former mayor of Mount Olive Township, maintained the reorganization wont affect mosquito control programs, but it will save money.

Nothing is changing other than were folding the office responsibilities into Public Works, Scapicchio said.

Scapicchio said that as part of the savings, the county will have to complete just one audit for both the mosquito control commission and the public works department.

Other potential savings are expected through centralized purchasing, vehicle inspection and licensing.

The rest is here:
Health officials worry county freeholders could bite into mosquito control program

Liberia: We Must Leave No Stone Unturned in the Campaign Against HIV/Aids

We must leave no stone unturned in dealing with the growing issue of HIV/AIDS in our beloved country, Liberia. By this, we should do away with utterances and comments that have the inclination to stigmatize those living with the virus.

Our guidance is predicated on keen surveillance that stigmatization and discrimination against people living with HIV/AIDS continue to be a major impediment to the fight against this killer disease in our country. We believe most people, if not all of who are tested positive, will not openly declare their status once people living with HIV/AIDS continue to be stigmatized and discriminated.

Honestly, the continued fight against HIV/AIDS will be meaningless if the stigmatization and discrimination against those living with the virus does not stop. It is very important that we stop the unnecessary debate concerning where, when and how people get the disease and also we must dispel religious perception that people living with HIV/AIDS are cursed by God.

We encourage our religious leaders to also help take the issue of HIV/AIDS very seriously and that they must discourage utterances and comments that have the propensity to stigmatize those living with the virus. Like the campaign against the crippling Polio Disease, we think, by showing compassion and love for HIV/AIDS victims, the fight against the deadly disease will also be successful.

To this end, we again urge those in the habit of stigmatizing and discriminating HIV/AIDS victims to desist or else, the launched campaign against the killer disease will not achieve its desired objectives.

See the article here:
Liberia: We Must Leave No Stone Unturned in the Campaign Against HIV/Aids

Canadian doctors develop new vaccine for tuberculosis

;

Canadian scientists say theyve developed a vaccine for tuberculosis that could lead the way to ending the global fight against the virus with strains that have grown resistant to drugs. Matt McClain for The Washington Post via Getty Images

TORONTO Canadian scientists say theyve developed a vaccine for tuberculosis that could lead the way to ending the global fight against the virus with strains that have grown resistant to drugs.

McMaster University doctors in Hamilton, Ont., say theyre the first in the world to develop the treatment, which is based on a genetically-modified cold virus.

Tuberculosis is a serious public health threat. One-third of the worlds population is infected with the organism that causes tuberculosis, and it remains the top infectious killer of people only secondary to HIV; yet the current vaccine used to prevent it is ineffective, McMasters Dr. Fiona Smaill said in a news release.

Shes the chair of the department of pathology and molecular medicine at McMasters DeGroote School of Medicine.

Read more:Canadian researchers develop disease outbreak surveillance

The vaccine is meant to act as a booster to the only TB vaccine thats currently available its called Bacille Calmette Guerin or BCG. That treatment was developed in the 1920s and is part of the World Health Organizations immunization program in countries around the world.

Nunavut also uses BCG its the only Canadian jurisdiction where the vaccine is routinely doled out because of high rates of TB in the territory.

Read more:Snapshot of health care in Canada: What you need to know

Original post:
Canadian doctors develop new vaccine for tuberculosis